Gender difference in survival of resected non–small cell lung cancer: Histology-related phenomenon?

Distribution of Noguchi's type for smaller adenocarcinoma according to gender. There are significantly more Noguchi's type A or B in women and more Noguchi's type D, E, or F in men.

Survival curves according to gender. The overall 5-year survival is 81% for women (n = 1081) and 70% for men (n = 1689). Women show significantly better survival than men (P < .001).

Survival curves according to gender in adenocarcinoma (A) and non-adenocarcinoma (B). In adenocarcinoma, the overall 5-year survival is 75% for men (n = 1042) and 84% for women (n = 1012). This gender difference is significant (P < .001). In non-adenocarcinoma, the overall 5-year survivals of men (n = 647) and women (n = 69) are 64% and 58%, respectively. This gender difference in survival is not significant (P = .299).

Survival curves according to gender of pathologic stage I in adenocarcinoma (A) and non-adenocarcinoma (B). The overall 5-year survival of pathologic I in adenocarcinoma for women is significantly better than that for men (95% vs 87%, P < .001). There is no significant gender difference in survival of pathologic stage I in non-adenocarcinoma (79% vs 74%, P = .313).

Survival curves according to gender of pathologic stage II or higher in adenocarcinoma (A) and non-adenocarcinoma (B). There is a significant gender difference in survival in the subset of adenocarcinoma (57% in women, 51% in men, P = .017), but not in non-adenocarcinoma (50% in men, 48% in women, P = .770).

Survival curves of propensity score matched-gender pairs. There is no significant gender difference in survival (P = .69).